Category Archives: Biotechnology

Marc Beers is Committed to Improving the Health of its Customers

Marc Beer, businessman and entrepreneur, OS the co-foumder of Renovia, Inc

, and currently the CEO ( Chief Executive Officer) and chairman of the company. The entity is a medical technology company based on Boston, Massachusetts that is developing diagnostic and therapeutic devices that are used to treat pelvic floor disorders such as urinary incontinence. The company recently completed a round of funding and closed that round with a total of $42 million. Of that, $10 million was from Venture capital and $32 million was from Series B funding. The first product Renovia developed was a product called Leva which received FDA (Food and Drug Administration) approval on April,of 2018.

 

An early investor in Renovia was the Longwood Fund, an investing firm that focuses on healthcare. The Series B funding round was led by Perceptive Advisors and Ascenion Ventures. The funds from the capital raising effort will support the development and testing of four additional diagnostic and therapeutic products. Included in the effort will be an enhancement of the Leva product. Renovia is excited to have the support of those interested on the investment of such healthcare aspects. The products will ultimately benefit millions of women who differ from pelvic floor disorders. The products will ultimately benefit the millipn S of women who suffer from pelvic floor disorders. The combination of state of the art technology and funding will allow customers access to data and information that will allow them to make better informed decisions and add to the quality of life of many. The overall upshot is to help lower the cost of certain aspects of healthcare for users.

 

Marc Beer had more than 25 years of experience in the development and commercial marketing of pharmaceuticals, biotechnology and medical devices. In April of 2000, Beets was the founder and CEO of a biotechnogy company that focused on the collection and preservation process of umbilical cord blood stem cells. During his tenure at ViaCell, his leadership brought the company from start-up to a wry robust commercial enterprise. The company grew from a handful of employees to more than 300 and in 2007 the company was acquired by PerkinElmer.

 

Mr. b.Beets also served as a board of director member of Erytech Pharma, which is a biopharmaceutical company. Early in his career, Beers handled employment opportunities and challenges with a company called Genzyme. He was the Vice President of Global Marketing and he was responsible for launching several products that addressed several rate doase issues globally. He also served on the Governing Board of the Biotechnology Industry Organization Emerging Companies, as well as the Commonwealth of Massachusetts of Mass Life Science Board.

 

Marc Beets earned a Bachelor of Science degree (BS) from Miami University. He is also a mbet of the Miami University Business Advisory Council and a former member of the Notre Dame Graduate Studies Research and Advisory Council. Learn more : https://renoviainc.com/leadership/

Marc D. Beer

Marc D. Beer is a biotechnology executive with more than 20 years of experience in the diagnostic and pharmaceutical industries. Mr. Beer was the Chief Executive Officer of Aegerion Pharmaceuticals which produced various types of medications to treat specific diseases and illnesses.

 

Earlier in his biotech career, Marc held managerial positions at the following firms:

 

* ViaCell – company that specialized in preserving the blood stem cells of the umbilical cord

 

* Genzyme (Abbott Laboratories) – company that helped to develop treatments for rare diseases that were once considered untreatable.

 

* OvaScience – company that specializes in new treatments for couples and women struggling with infertility. OvaScience is merging with Millendo Therapeutics

 

* ERYTech Pharma – biopharmaceutical company that develops therapies for certain cancer and rare genetic diseases

 

* TxCell – company that develops T-cell immunotherapy systems

 

Marc Beer believes in making life better for people. For this reason, he created “Renovia, Inc.,” a medical diagnostic and therapeutic company. Marc serves as its Chief Executive Officer at its headquarters in Boston. Renovia will conduct clinical trials, produce medical products and develop many commercial ventures.

 

Marc founded Renovia to also research treatments to address the pelvic floor disorder. A pelvic floor issue involves incontinence which widely affects women around the globe. The Boston financial community stepped up with Marc enabling him to raise $42.3 million in financing for Renovia, Inc.

 

The FDA has already approved a Renovia product to address this health problem, which is the Leva device. The FDA has also approved certain drugs like the HoFH – homozygous familial hypercholesterolemia which is a rare disease that keeps high cholesterol levels within the body.

 

The Leva device is manufactured to strengthen the pelvic floor in women. The device is very innovative because it contains a sensor system that allows users to see the position of their pelvic floor muscles and to monitor any movement that is exerted during exercises.

 

Marc Beer received his Bachelor of Science degree from Miami University in Oxford, Ohio. He is also very active on medical and research boards like Minerva Neurosciences of Waltham, MA, where he serves as Chairman. He is Chairman of the Board at Good Start Genetics, Inc. of San Francisco, CA.

 

Marc also sits on the Board of Directors at the Biotechnology Innovation Organization headquartered in Washington, DC. and the Joe Andruzzi Cancer Foundation of North Attleboro, MA. Marc D. Beer is also a board member at the University of Notre Dame and RenaMed Biologics, Inc. Learn more : https://www.slideshare.net/MarcBeer

 

Clay Siegall Founder of Seattle Genetics With Long History in Biotechnology

Clay Siegall is the founder of Seattle Genetics and he has a long history as a founder of the company. The company is working on radical therapies for cancers which are a direct result of his research in an academic laboratory. Dr. Siegall has built worldwide collaborations with the benefit of his technology company, as many other individuals have seen the benefit of the company’s products and services for their own companies. The portfolio of preclinical/clinical products which Seattle Genetics makes available to their customers is nothing short of amazing.

The company Seattle Genetics is a pioneer in using antibody conjugates to treat lymphoma patients. It has the ability to prevent tumors from becoming malignant. Many collaborations with industry have been quite profitable, producing over $65 million in profits since 2001 which has enabled the company to expand their product line. Their therapies have the potential to treat many different malignant tumors and they have had licensing agreements approved in order for many of the other applications to be considered.

These antibody-based therapies for cancer have been considered to be one of the top biotechnology innovations. Globally, one of their therapies has been able to successfully cure thousands of patients around the world. Some patients are at a high risk for a relapse, so the therapies have been created in order to prevent that from happening. In either case, the company’s pipeline is diverse and designed to be great options for treating individuals whom have been afflicted with cancer and other serious illnesses.

With all of these great accomplishments, Clay Siegall has had a successful career without a doubt. He began as a professor and holds a Ph.D degree. From there, he has expanded on to the private sector and worked for many biotechnology companies. As an accomplished individual, he also provides mentorship and guidance to many students whom are looking to break into the biotech world. He also serves on the board of directors of many other biotechnology companies such as Alder BioPharmaceuticals, Mirna Therapeutics, and has even worked at the national institutes of health.